Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
+1q retains prognostic significance in era of daratumumab-based treatments; isolated +1q remains independent factor of adverse prognosis (e.g. shorter PFS (HR 4.77) and TTNT (3.83), further worsened by co-existing HiRCAs.”
Title: Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab-Based Regimens
Authors: Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Cecilia Fabiano, Adriana Maria Rita Alfano, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Barbara Gamberi
You can read the Full Article in European Journal of Haematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
